Cleared Traditional

K113221 - NAMSA BIOLOGICAL INDICATOR SPORE STRIPS (FDA 510(k) Clearance)

Class II General Hospital device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2012
Decision
178d
Days
Class 2
Risk

K113221 is an FDA 510(k) clearance for the NAMSA BIOLOGICAL INDICATOR SPORE STRIPS. Classified as Indicator, Biological Sterilization Process (product code FRC), Class II - Special Controls.

Submitted by North American Science Assoc., Inc. (Toledo, US). The FDA issued a Cleared decision on April 27, 2012 after a review of 178 days - an extended review cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.2800 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all North American Science Assoc., Inc. devices

Submission Details

510(k) Number K113221 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 01, 2011
Decision Date April 27, 2012
Days to Decision 178 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
49d slower than avg
Panel avg: 129d · This submission: 178d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code FRC Indicator, Biological Sterilization Process
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.2800
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FRC Indicator, Biological Sterilization Process

All 205
Devices cleared under the same product code (FRC) and FDA review panel - the closest regulatory comparables to K113221.
Celerity 5 HP Biological Indicator (LCB052)
K260766 · STERIS Corporation · Apr 2026
Celerity™ 20 HP Biological Indicator
K252680 · STERIS Corporation · Sep 2025
Terragene® Bionova® BT20 Biological Indicator
K251122 · Terragene · Aug 2025
Celerity 5 HP Biological Indicator (LCB052)
K251452 · Steris · Jun 2025
Celerity 5 HP Biological Indicator (LCB052)
K250044 · STERIS Corporation · Feb 2025
Celerity Incubator
K250061 · STERIS Corporation · Feb 2025